NCT01062620View on ClinicalTrials.gov

A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 31, 2011

Conditions
Solid Tumors
Interventions
DRUG

AXL1717

Phase I study with increasing dosage and treatment duration

Trial Locations (1)

SE-75185

Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

Axelar AB
All Listed Sponsors
lead

Axelar AB

INDUSTRY

NCT01062620 - A Dose Escalating Clinical Trial of the IGF-1 Receptor Inhibitor AXL1717 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter